Compound Collection November 2023: Molecules from November of Potential Interest
Other articles you may be interested in
August 2024 Molecule Roundup | >70 Molecules to Know
In this article, you'll find a curated selection of >70 molecules from August that piqued our interest, highlights of some of our favorites, and explanations of why they're worth watching.
Six Deals and Funding Rounds from July You May Have Missed
In case you missed anything while you were away on summer holiday, here’s a recap of six notable deals from July to get you up to speed.
Patent Highlights: USP19 Inhibitors, KCC2 Potentiators, Nrf2 Inhibitors, Additional Polθ Inhibitors, and More!
Our October patent highlights cover a diverse array of drug discovery IP disclosures. From piperidine-based USP19 inhibitors and small molecule GIPR antagonists for obesity to KCC2 potentiators for epilepsy, the month delivered a number of exciting IP developments. Other notable discoveries include MTA-cooperative PRMT5 inhibitors, direct-acting influenza antivirals against a novel target, Nrf2 activators for heart failure, and a slew of Polθ inhibitors for HR-deficient cancers.
July’s Molecules on the Move
To get you up to speed, here’s a recap of July’s molecules on the move, including potential upcoming approvals, key interim trial readouts, new IND submissions, and trial setbacks.
Key Clinical Compound Updates from November 2024
This summary of major clinical updates from November 2024 covers FDA approvals, the initiation of new clinical trials, notable trial outcomes for key drug candidates, and news on paused and discontinued trials and programs.
